37662
document
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive , node-positive breast cancer ? International Breast Cancer Study Group Trials VII and 12-93 . To compare the efficacy of chemoendocrine treatment with that of endocrine treatment ( ET ) alone for postmenopausal women with highly endocrine responsive breast cancer . In the International Breast Cancer Study Group ( IBCSG ) Trials VII and 12-93 , postmenopausal women with node-positive , estrogen receptor ( ER ) -positive or ER-negative , operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment . Results were analyzed overall in the cohort of 893 patients with endocrine-responsive disease , and according to prospectively defined categories of ER , age and nodal status . STEPP analyses assessed chemotherapy effect . The median follow-up was 13 years . Adding chemotherapy reduced the relative risk of a disease-free survival event by 19 % ( P = 0.02 ) compared with ET alone . STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression ( P = 0.07 ) , or for the cohort with one positive node ( P = 0.03 ) . Chemotherapy significantly improves disease-free survival for postmenopausal women with endocrine-responsive breast cancer , but the magnitude of the effect is substantially attenuated if ER levels are high .
37663
Intervention_Pharmacological
adjuvant chemotherapy
37664
Intervention_Pharmacological
chemoendocrine treatment
37665
Intervention_Pharmacological
endocrine treatment ( ET )
37666
Intervention_Pharmacological
chemotherapy
37667
Intervention_Pharmacological
endocrine therapy
37668
Intervention_Pharmacological
combined chemoendocrine treatment
37669
Intervention_Pharmacological
chemotherapy
37670
Intervention_Pharmacological
ET
37671
Intervention_Pharmacological
Chemotherapy
37672
Outcome_Other
efficacy
37673
Outcome_Other
STEPP analyses assessed chemotherapy effect
37674
Outcome_Mortality
relative risk of a disease-free survival event
37675
Outcome_Mortality
levels of ER expression
37676
Outcome_Mortality
disease-free survival
37677
Outcome_Other
for
37678
Participant_Condition
postmenopausal
37679
Participant_Sex
women
37680
Participant_Condition
breast cancer
37681
Participant_Condition
Breast Cancer
37682
Participant_Condition
postmenopausal
37683
Participant_Age
women
37684
Participant_Condition
breast cancer
37685
Participant_Sample-size
12-93
37686
Participant_Condition
postmenopausal
37687
Participant_Sample-size
women
37688
Participant_Condition
breast cancer
37689
Participant_Sample-size
893
37690
Participant_Condition
endocrine-responsive disease
37691
Participant_Condition
postmenopausal
37692
Participant_Sample-size
women
37693
Participant_Condition
breast cancer